Lyell Immunopharma Inc. reported a net loss of $52.2 million for the first quarter ended March 31, 2025, an improvement from the net loss of $60.7 million in the same period of 2024. The reduction in net loss was mainly attributed to the absence of $13.0 million in impairment expenses recognized in the prior year, partially offset by a $3.0 million decrease in interest income. Research and development expenses slightly increased to $43.4 million from $43.2 million in the first quarter of 2024, driven by a $3.1 million rise in personnel expenses due to severance costs linked to the closure of the West Hills manufacturing facility. General and administrative expenses increased to $14.0 million from $13.5 million in the same period of the previous year, mainly due to personnel-related costs from the acquisition of ImmPACT and severance expenses. As of March 31, 2025, Lyell reported cash, cash equivalents, and marketable securities totaling $330.1 million, down from $383.5 million as of December 31, 2024. The company indicated that these resources are expected to meet its working capital and capital expenditure needs into 2027. A significant business development includes the presentation of an abstract on Stim-R™, a synthetic stimulatory agent, at the American Association for Cancer Research Annual Meeting 2025, highlighting its potential to enhance tumor-infiltrating lymphocyte manufacturing processes.